| Name | Title | Contact Details |
|---|
Global Seven is a Franklin, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches.
IQSynthesis is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry. ACD’s products and services are based on its proprietary RNAscope® Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development. These internal and external efforts will continue to position ACD as a leader in molecular diagnostics and companion diagnostics. The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.
Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines that will meet serious unmet medical needs in oncology and other diseases. Incyte is a company driven by innovation, and we believe that investment in cutting-edge science and the rigorous pursuit of R&D excellence can translate into new medicines for serious unmet medical needs that positively impact patients` lives. Incyte has a diverse and growing portfolio of first-in-class and best-in-class product candidates, including both small and large molecules. Incyte is headquartered in Wilmington, Delaware with operations in 10 European countries and Japan. Our more than 1,000 employees are led by distinguished executives with proven records of success. We are proud to have been recognized by Forbes as one of the World`s Most Innovative Companies for each of the past three years.